XORTX Therapeutics Regains Nasdaq Compliance, Resolving Minimum Bid Price Deficiency
XRTX sits 72% above its 52-week low of $1.725 on elevated volume (59× avg).
Summary
XORTX Therapeutics Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, successfully resolving the deficiency after implementing a reverse stock split.
Key Events · Corporate Governance and Compliance · XRTX
-
Regains Nasdaq Minimum Bid Price Compliance
XORTX Therapeutics Inc. received a letter of compliance from Nasdaq, confirming it has met the Rule 5550(a)(2) minimum bid price requirement. The company's shares traded above US$1.00 for at least 10 consecutive trading days, with compliance achieved on April 17, 2026.
-
Follows Reverse Stock Split
This compliance was achieved after the company implemented a 1-for-5 reverse stock split of its common shares on April 6, 2026, which facilitated the stock price meeting the Nasdaq threshold.
Analysis · XRTX · Life Sciences
This filing is important as XORTX Therapeutics Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement, removing a significant delisting risk. For a company of its size, maintaining a Nasdaq listing is crucial for investor visibility, liquidity, and access to capital markets. The compliance was achieved following a 1-for-5 reverse stock split on April 6, 2026, which allowed the stock to trade above the $1.00 threshold for the required consecutive days. This resolution provides stability regarding its listing status.
At the time of this filing, XRTX was trading at $2.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $1.73 to $7.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.